Azenta Inc (AZTA)vsBecton Dickinson and Company (BDX)
AZTA
Azenta Inc
$34.20
+0.32%
HEALTHCARE · Cap: $1.48B
BDX
Becton Dickinson and Company
$179.23
-1.80%
HEALTHCARE · Cap: $49.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 3563% more annual revenue ($22.48B vs $613.81M). BDX leads profitability with a 4.2% profit margin vs -20.0%. AZTA appears more attractively valued with a PEG of 0.53. AZTA earns a higher WallStSmart Score of 57/100 (C).
AZTA
Buy57
out of 100
Grade: C
BDX
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+35.0%
Fair Value
$46.86
Current Price
$34.20
$12.66 discount
Margin of Safety
+11.0%
Fair Value
$202.87
Current Price
$179.23
$23.64 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of -11.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Premium valuation, high expectations priced in
ROE of 3.9% — below average capital efficiency
4.2% margin — thin
Earnings declined 31.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 12.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : BDX
The strongest argument for BDX centers on Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bear Case : AZTA
The primary concerns for AZTA are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin. Thin 4.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZTA profiles as a turnaround stock while BDX is a value play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.39 — expect wider price swings.
AZTA is growing revenue faster at 12.0% — sustainability is the question.
BDX generates stronger free cash flow (509M), providing more financial flexibility.
Bottom Line
AZTA scores higher overall (57/100 vs 52/100) and 12.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.
Visit Website →Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?